At the Dubin Breast Center, we provide excellence in all facets of breast cancer care. In addition, our mission includes tirelessly pursuing better outcomes for breast cancer patients. By housing multiple clinical services under one roof, we foster interdisciplinary and translational research to help achieve this goal. The Dubin Breast Center and Tisch Cancer Institute faculty members have a wide range of breast cancer research projects, including the following:

• Providing a high-risk surveillance program for individuals at high risk for developing breast cancer
• Identifying the causes of breast cancer
• Studying the reasons for disparities in breast cancer treatment
• Finding novel approaches to treating breast cancer
• Understanding breast cancer dormancy
• Exploring new ways to prevent and diagnose breast cancer
• Evaluating the safety and efficacy of new and existing breast cancer treatments through clinical trials

How to Participate in Research

When you participate in a clinical trial, you help yourself—and everyone else. Being part of a clinical trial gives you a chance to receive a new treatment that might otherwise be unavailable to you. It also helps us work to improve the standard of care for current and future breast cancer patients. The Dubin Center does not do research on its own. Our doctors work closely with partners in the pharmaceutical industry in our research efforts. We also work with cooperative groups through the National Cancer Institute such as Alliance for Clinical Trials in Oncology, Cancer and Leukemia Group B, and the American College of Radiology Imaging Network.

Open Clinical Trials at the Dubin Breast Center

We are always involved in numerous studies to examine breast cancer imaging, genetics, radiation, chemotherapy, surgery, prevention, and treatment disparities. Speak with your Dubin health care team if you have questions about or interest in any of our current clinical trials. Often, clinical trials have specific criteria that you must meet to participate.

Ductal Carcinoma in Situ (DCIS) Trials

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS (COMET)

• Contact: Kereeti V. Pisapati, MS; (212) 241-2475

Pre-Surgery Treatment Trials (Neoadjuvant)

Patient-Derived Xenograft (PDX) Modeling of Treatment Response for Triple Negative Breast Cancer

• Contact: Kereeti V. Pisapati, MS; (212) 241-2475

NRG-BR005: Assessing the Accuracy of Tumor Biopsies after Chemotherapy to Determine If Patients Can Avoid Breast Surgery

• Contact: Kereeti V. Pisapati, MS; (212) 241-2475

Alliance A011202: Comparison of Axillary Lymph Node Dissection with Axillary Radiation for Patients with Node-Positive Breast Cancer Treated with Chemotherapy

• Contact: Ronald Couri; (212) 241-6308

A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide followed by Paclitaxel/ Trastuzumab/Pertuzumab (AC→THP) and Docetaxel/Carboplatin/Trastuzumab/ Pertuzumab (TCHP) for Early Her2Neu Positive Breast Cancer

• Contact: Gargi Joshi, MS; (212) 824-7320

Post-Surgery Treatment Trials (Adjuvant)

Hypnosis to Reduce Aromatase Inhibitor Pain and Improve Adherence

• Contact: Andrea Lopez, MPH (212) 659-5557

Treating Cancer-Related Fatigue Through Systemic Light Exposure (Light for Fatigue Study)

• Contact: Christopher Hickson; (212) 824-7193

NRG BR003: A Randomized Phase III Trial of Adjuvnat Therapy Comparing Douxorubicin Followed by Weekly Paclitaxel with or without Carboplatin for Node Positive or High-Risk Node Negative Triple-Negative Breast Cancer

• Contact: Christopher Hickson; (212) 824-7193

Alliace A011404: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

• Contact: Gargi Joshi, MS; (212) 824-7320

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial

• Contact: Gargi Joshi, MS; (212) 824-7320

Immunotherapy Trials

SWOG S1418: A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with ≥ 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemotherapy

• Contact: Gargi Joshi, MS; (212) 824-7320

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) versus Treatment of Physician's Choice (TPC) in Subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) Who Have Failed at Least Two Prior Chemotherapy Regimens for Metastatic Disease

·         Contact: Annie Gevertz; (212) 824-7351

Metastatic Breast Cancer (MBC) Trials

A Phase 1B, Multicenter, Two-Part, Open Label Study of DS-8201A, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2) Antibody Drug Conjugate (ADC), in Combination with Nivolumab, an Anti-PD-1 Antibody for Subjects with Her2 Expressing Advanced Breast and Urothelial Cancer

• Contact: Christopher Hickson; (212) 824-7193

Study of Efficacy of Riobociclib after Progression on CDK4/6 Inhibition in Patients with HR+ HER2- Advanced Breast Cancer (MAINTAIN)

• Contact: Annie Gevertz; (212) 824-7351

The MATCH Screening Trial: Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma

• Contact: Christopher Hickson; (212) 824-7193

Comparison of Single-Agent Carboplatin versus the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple Negative Breast Cancer

• Contact: Gargi Joshi, MS; (212) 824-7320

ASPIRE: A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, Her2-positive Metastatic Breast Cancer

• Contact: Annie Gevertz; (212) 824-7351

A Phase I/II Trial of Leflunomide in Women with Previously Treated Metastatic Triple Negative Cancers

• Contact: Gargi Joshi, MS; (212) 824-7320